Donna Shu-Han Lin

Donna Shu-Han Lin

Auto-generated profile, based on publicly available information

Donna Shu-Han Lin

Division of Cardiology, Department of Internal Medicine, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 December 2023 in Journal of the American Heart Association
Verified
Journal Article
Open access
DLDonna Shu‐Han Lin
Donna Shu‐Han Lin
HLHao‐Yun Lo
Hao‐Yun Lo
KHKuan‐Chih Huang
Kuan‐Chih Huang
TLTing‐Tse Lin
Ting‐Tse Lin
JLJen-Kuang Lee
Jen-Kuang Lee
Background: Although older patients with atrial fibrillation are at heightened risk of thromboembolic and bleeding events, their optimal treatment choice remains uncertain. Methods and Results: This meta‐analysis was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses guidelines. We searched the PubMed, EMBASE, and Cochrane databases for randomized controlled trials that compared thromboembolic or bleeding outcomes between a direct oral anticoagulant (DOAC) and a vitamin K antagonist (VKA) and reported outcomes for patients aged ≥75 years with atrial fibrillation. The efficacy outcome was the composite of stroke and systemic embolism. Safety outcomes included major bleeding, any clinically relevant bleeding, and intracranial hemorrhage. Each DOAC and VKA was compared pairwise in a network meta‐analysis. High‐ and low‐dose regimens and factor IIa and Xa inhibitors were also compared. Seven randomized controlled trials were included in the analysis. Stroke and systemic embolism risks did not differ significantly among DOACs. There were no significant differences in major bleeding between each DOAC and VKA. Intracranial hemorrhage risk was significantly lower with dabigatran, apixaban, and edoxaban than with VKA and rivaroxaban, which had similar risks. High‐dose regimens led to lower risks of stroke or systemic embolism compared with VKA and low‐dose regimens, with both doses having similar bleeding risks. Conclusions: In patients aged ≥75 years with atrial fibrillation, DOACs were associated with fewer thromboembolic events compared with VKA, whereas dabigatran, apixaban, and edoxaban were associated with lower risks of intracranial hemorrhage compared with VKA and rivaroxaban. Registration: URL: www.crd.york.ac.uk/prospero/ . Unique identifier: CRD42022329557.

11 December 2020 in The Journal of Clinical Hypertension
Verified
Journal Article
Open access
PDF file
DLDonna S.‐H. Lin
Donna S.‐H. Lin
TWTzung-Dau Wang Wang
Tzung-Dau Wang Wang
PBPeera Buranakitjaroen
Peera Buranakitjaroen
CCChien-yu Chen
Chien-yu Chen
HCHao-Min Cheng
Hao-Min Cheng
TNThe Hope Asia Network
The Hope Asia Network
Hypertension is a worldwide epidemic that continues to grow, with a subset of patients responding poorly to current treatment available. This is especially relevant in Asia, which constitutes 61% of the global population. Hypertension in Asia is a unique entity that is often salt‐sensitive, nocturnal, and systolic predominant. Sacubitril/valsartan is a first‐in‐class angiotensin receptor neprilysin inhibitor that was first used in heart failure with reduced ejection fraction. Sacubitril inhibits neprilysin, a metallopeptidase that degrades natriuretic peptides (NPs). NPs exert sympatholytic, diuretic, natriuretic, vasodilatory, and insulin‐sensitizing effects mostly via cyclic guanosine monophosphate (cGMP)‐mediated pathways. As an antihypertensive agent, sacubitril/valsartan has outperformed angiotensin II receptor type 1 blockers (ARBs), with additional reductions of office systolic blood pressures ranging between 5 and 7 mmHg, in multiple studies in Asia and around the globe. The drug was well tolerated even in the elderly or those with chronic kidney disease. Its mechanisms of actions are particularly attractive for treatment of hypertension in Asia. Sacubitril/valsartan offers a novel, dual class, single‐molecule property that may be considered as first‐line antihypertensive therapy. Further investigations are needed to validate its safety for long‐term use and to explore other potentials such as in the management of insulin resistance and obesity, which often coexist with hypertension in Asia.

16 May 2022 in International Journal of Obesity
Verified
Journal Article
Closed access
PDF file
DLDonna Shu-Han Lin
Donna Shu-Han Lin
HLHao-Yun Lo
Hao-Yun Lo
AYAn-Li Yu
An-Li Yu
JLJen-Kuang Lee
Jen-Kuang Lee
KCKuo-Liong Chien
Kuo-Liong Chien

1 September 2022 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
HLHao-Yun Lo
Hao-Yun Lo
YLYu-Sheng Lin
Yu-Sheng Lin
DLDonna Shu-Han Lin
Donna Shu-Han Lin
JLJen-Kuang Lee
Jen-Kuang Lee
WCWEN-JONE CHEN
WEN-JONE CHEN
Peripheral artery disease (PAD) has been increasingly prevalent, with more than 200 million people estimated to have PAD worldwide.1,2 This disease has been associated with substantially higher risks of all-cause and cardiovascular (CV) death3 and is more common among patients with kidney failure than the general population.4,5 Patients with PAD who are receiving dialysis are also at higher risk of experiencing major adverse limb events (including amputation and hospitalization for critical limb ischemia [CLI]) and death.6-9

19 July 2024 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Closed access
DLDonna Shu‐Han Lin
Donna Shu‐Han Lin
HLHao‐Yun Lo
Hao‐Yun Lo
KHKuan‐Chih Huang
Kuan‐Chih Huang
TLTing‐Tse Lin
Ting‐Tse Lin
JLJen‐Kuang Lee
Jen‐Kuang Lee
LLLian‐Yu Lin
Lian‐Yu Lin

6 August 2024 in Mayo Clinic Proceedings
Verified
Journal Article
Closed access
DLDonna Shu-Han Lin
Donna Shu-Han Lin
KHKuan-Chih Huang
Kuan-Chih Huang
TLTing-Tse Lin
Ting-Tse Lin
JLJen-Kuang Lee
Jen-Kuang Lee
LLLian-Yu Lin
Lian-Yu Lin